CAMP4 Therapeutics (CAMP) has filed for a proposed initial public offering (IPO). The company describes itself as a clinical-stage biopharmaceutical company focused on developing RNA-based therapeutics to enhance gene expression and restore healthy protein levels for the treatment of a wide range of genetic diseases. Regulatory RNA, or regRNA, plays a central role in regulating the expression of every protein-coding gene, helping to activate and suppress genes. CAMP4’s approach aims to enhance the expression of messenger RNA (mRNA) by using regRNA, which form localized complexes with transcription factors and regulate gene expression. Their patented RNA Actuating Platform (RAP Platform) allows them to rapidly and systematically identify and characterize active regulatory elements that control each expressed gene, as well as tens of thousands of regRNA enhancer and promoter sequences that control protein-coding genes. Once a disease-associated target gene is identified, CAMP4 applies their RAP platform to identify the controlling regRNA and quickly create new candidates based on antisense oligonucleotides (ASOs), which they also call RNA Actuators. These ASOs are designed to bind to the identified regRNA and enhance the expression of the target gene in a specific and controlled manner. Initially, they are focused on metabolic diseases and central nervous system (CNS) disorders with validated disease biology, but they believe that their RAP platform enables them to work with a broad spectrum of genetic diseases where even a slight increase in protein expression can have clinical significance. J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair will serve as underwriters for the IPO. (This article has been translated using artificial intelligence. For more information, please refer to our Terms of Use.)

Источник